Immix Biopharma (IMMX) Other financing activities (2021 - 2025)

Immix Biopharma has disclosed Other financing activities across 5 years of filings, most recently posting $602109.0 for Q1 2025.

• Other financing activities for Q1 2025 came in at $602109.0, down 2.24% year-over-year; the trailing twelve-month figure through Mar 2025 was $2.4 million (up 6.74% YoY), and the FY2024 annual result was $2.4 million, up 23.15% from the prior year.
• Other financing activities came in at $602109.0 for Q1 2025 at Immix Biopharma, down from $613153.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $737325.0 in Q3 2023 to a low of $4247.0 in Q1 2021.
• The 5-year median for Other financing activities is $329919.0 (2023), against an average of $334214.3.
• Across the five-year window, Other financing activities surged 1432.23% in 2022 and slipped 14.72% in 2024, its largest moves.
• Immix Biopharma's Other financing activities stood at $122152.0 in 2021, then jumped by 88.37% to $230094.0 in 2022, then soared by 86.18% to $428385.0 in 2023, then surged by 43.13% to $613153.0 in 2024, then slipped by 1.8% to $602109.0 in 2025.
• The last three Other financing activities figures came in at $602109.0 (Q1 2025), $613153.0 (Q4 2024), and $628806.0 (Q3 2024), per Business Quant data.